Literature DB >> 3770017

Liver drug metabolism and blood pressure response to a lipophilic and hydrophilic beta blocker.

S Säkö, E A Sotaniemi, M Anttila.   

Abstract

The role of liver drug metabolism on blood pressure (BP) response to a lipophilic (propranolol) and hydrophilic (sotalol) beta blocker in thirty hypertensive patients was studied. Ten patient treated with diuretics were classified according to plasma antipyrine clearance rate as rapid and slow metabolizers. They were first treated for one month with propranolol and then for one month with sotalol at equivalent dosage. Four patients, classified as rapid drug metabolizers had a better response to sotalol, 139 (SD 13)/92 (SD 6) mmHg, than to propranolol, 164 (21)/104 (10) mmHg. For the other six patients, with slow drug metabolism, the response to propranolol, 142 (8)/95 (8) mmHg was equal to sotalol, 143 (19)/93 (8) mmHg. Twenty patients were randomly divided into two groups. The patients in these groups were similar as to sex, age, body mass index, BP and rate of drug metabolism. The subjects in the first group were treated with propranolol and diuretic and those in the second with sotalol and diuretic. The BP response was equal in both groups, propranolol 147 (14)/96 (7) mmHg and sotalol 143 (12)/95 (9) mmHg after two years' follow-up. The rate of drug metabolism must be considered when evaluating response to lipophilic but not to hydrophilic beta blocker.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3770017     DOI: 10.1007/BF03189831

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  20 in total

1.  Role of blood pressure in cardiovascular disease: the Framingham Study.

Authors:  W B Kannel
Journal:  Angiology       Date:  1975-01       Impact factor: 3.619

Review 2.  Antihypertensive drugs: clinical pharmacology and therapeutic use.

Authors:  G L Wollam; R W Gifford; R C Tarazi
Journal:  Drugs       Date:  1977-12       Impact factor: 9.546

3.  Separation and spectrofluorometric assay of the -adrenergic blocker sotalol from blood and urine.

Authors:  E R Garrett; K Schnelle
Journal:  J Pharm Sci       Date:  1971-06       Impact factor: 3.534

4.  Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg.

Authors: 
Journal:  JAMA       Date:  1967-12-11       Impact factor: 56.272

5.  Plasma propranolol levels in adults with observations in four children.

Authors:  D G Shand; E M Nuckolls; J A Oates
Journal:  Clin Pharmacol Ther       Date:  1970 Jan-Feb       Impact factor: 6.875

Review 6.  Drug interactions with cimetidine.

Authors:  A Somogyi; R Gugler
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

7.  Antihypertensive effect and plasma levels of labetalol. A comparison with propranolol and dihydrallazine.

Authors:  A Lehtonen; H Allonen; T Kleimola
Journal:  Int J Clin Pharmacol Biopharm       Date:  1979-02

Review 8.  The hypertensive diseases. Evidence that systemic hypertension is a greater risk factor to the development of other cardiovascular diseases than previously suspected.

Authors:  W C Roberts
Journal:  Am J Med       Date:  1975-10       Impact factor: 4.965

9.  Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group.

Authors: 
Journal:  JAMA       Date:  1979-12-07       Impact factor: 56.272

10.  The Australian therapeutic trial in mild hypertension. Report by the Management Committee.

Authors: 
Journal:  Lancet       Date:  1980-06-14       Impact factor: 202.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.